



Brown University Health - Institutional Biosafety Committee Minutes

February 2, 2026 Videoconference

Present: Dr. Jayasuriya, (Chairperson), Dr. Dubielecka-Szczerba (Vice Chairperson), Ms. Brilliant, Mr. Carrera, Mr. Dooner, Dr. Gregory, Dr. Helwig, Dr. Jackson, Dr. Li, Mr. McEvoy, and Mr. O'Reilly

Absent: Dr. Mehta,

Investigators Submitting Applications for Review: Dr. Liang

Guests: Dr. Choi

Support Staff: Ms. Poore

---

Note: Unless otherwise stated all motions were unanimously approved for 3 years.

After determining that quorum was met, Dr. Jayasuriya convened the meeting at 12:01 p.m. The following voting members were present when the meeting began: Dr. Jayasuriya, Dr. Dubielecka-Szczerba, Ms. Brilliant, Mr. Dooner, Dr. Gregory, Dr. Helwig, Dr. Li, Mr. McEvoy, and Mr. O'Reilly

Mr. Carrera, alternate for Mr. McEvoy, was present but did not participate in the vote for any item discussed at this meeting.

**Welcome and Opening Remarks:** The IBC chair read the COI statement aloud to remind members it is their responsibility to identify if they have a conflict of interest and to recuse themselves from review of that item.

**1 Review of Previous Minutes from 1/5/2026**

Committee Action: The minutes were approved as submitted.

Vote: Number of members present 9, Approved 9, Opposed 0, Abstained 0, Recused 0

NOTE: Dr. Jackson joined the meeting after the vote was taken to approve the minutes.

**2 New Studies DNA**

**3 Continuing Reviews DNA**

**3.1 [2028162-7] Conditionally Replicative Oncolytic Adenovirus**

**PI:** Olin Liang, Ph.D.  
**Reference Number:** 502223 adenovirus  
**Sponsor:** Brown Physicians Inc.  
**Submission Type:** Continuing Review/Progress Report  
**Review Type:** Full Committee Review  
**Primary Reviewer:** Stephen Gregory, Chathuraka Jayasuriya  
**Presented by:** Moon Jung Choi

Discussion:

- Dr. Choi provided an overview of the project which will use adenovirus constructs to kill glioblastoma cell lines.

- Dr. Choi noted the addition of 5 new adenovirus constructs and new personnel since the last review.
- Members requested clarification regarding the 7 cell lines listed on the progress report. Dr. Choi explained that HEK293 cells are used for the constructs. Glioblastoma cell lines are used to test the adenovirus constructs' ability to kill the tumor cells.

Requested corrections:

- Abstract, please expand to include a brief description of the rationale for this project
- Progress Report form, page 8, question 3c, please include the purpose/rationale for the newly added constructs
- Adenovirus Safety Sheet, add the new constructs

The IBC reviewed this project with regard to: potential virulence, pathogenicity or environmental stability of the agent; the types of manipulations planned; the source and nature of the inserted DNA sequences; and the host and vectors to be used. IBC assessment is as follows:

Recombinant DNA materials will be used in humans	Yes	X No
Recombinant DNA materials will be used in animals.	X Yes	No
Training and Expertise of personnel is adequate.	X Yes	No
Facilities, procedures and practices are adequate.	X Yes	No
Annual testing for replication competence is necessary.	Yes	X No
Biohazard containment level <u>X</u> BL2)		
Applicable Section of the NIH Guidelines: _____ III-D _____		

Committee Action: The committee voted to require modifications to secure approval. Dr. Jayasuriya will serve as the designated reviewer for the requested corrections.

Vote: Number of members present 10, Approved 10 Opposed 0 Abstained 0, Recused 0

**4 Revisions- Full Board DNA**

**5 Administrative Check-In**

**6 Expedited and Revision Reviews DNA**

**6.1 [2398787-2] AAV8-D377Y-mPCSK9**

**PI:** Wenliang Song, MD  
**Reference Number:** 504125  
**Sponsor:** Internal  
**Submission Type:** Response/Follow-Up  
**Review Type:** Expedited Review

**7 Administrative Reviews DNA**

**8 Exempt DNA**

**9 Other Business DNA**

**10 End of DNA Business**

**11 Start of Hazard Business**

**12 New Studies Hazard**

**13 Expedited and Revision Reviews Hazard**

**13.1 [1496875-4] USE OF HUMAN CELLS IN ANIMALS**

**PI:** Suzanne de la Monte, MD, MPH  
**Reference Number:** BLS 506119  
**Submission Type:** Continuing Review/Progress Report  
**Review Type:** Expedited Review

**14 Administrative Reviews Hazard**

**15 Other Business Hazard**

**The meeting adjourned at 12:13 p.m.**